Notícias e Atividades da Cornerstone Pharmaceuticals

A Cornerstone Pharmaceuticals pertence à Cyclo Therapeutics.

Cyclo Therapeutics é uma empresa listada sob o símbolo CYTH (US).

Fusão, aquisição e financiamento envolvendo Cyclo Therapeutics.

• Cyclo Therapeutics adquiriu Rafael Holdings (publicado em 28 de abril de 2025).

Veja o organograma con seus 10 executivos principais

Biografias mais buscadas da Cornerstone Pharmaceuticals

• John Goldberg, Chief Executive Officer
• Patrick Wilmerding, Director
• Joseph Stern, Director

Criar um alerta
para seguir os movimentos de executivos da Cornerstone Pharmaceuticals.

Cyclo Therapeutics possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Richard Saynor - Chief Executive Officer da Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Cornerstone Pharmaceuticals

• UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
• Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
• Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022
• Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
• Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.
• Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
• Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
• European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer
• Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer NYSE:RFL
• Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML) NYSE:RFL
• View more press releases Close

Redes sociais sobre Cornerstone Pharmaceuticals

• Cornerstone Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Cornerstone Pharmaceuticals na LinkedIn, X (Twitter) e YouTube